MMP2 and colorectal carcinoma: Moreover, a combined treatment with an ERK inhibitor (U0126) and baicalein against colorectal carcinoma (CRC) led to the synergistic reduction of MMP-2/9 expression, which is responsible for the anti-metastatic effect in CRC cells [35].